PFG Advisors Has $934,000 Stock Position in IQVIA Holdings Inc. $IQV

PFG Advisors trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 51.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 4,144 shares of the medical research company’s stock after selling 4,310 shares during the period. PFG Advisors’ holdings in IQVIA were worth $934,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. acquired a new stake in IQVIA in the fourth quarter worth about $25,000. Physician Wealth Advisors Inc. increased its position in IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after purchasing an additional 134 shares during the period. Westside Investment Management Inc. increased its position in IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after purchasing an additional 101 shares during the period. Measured Wealth Private Client Group LLC acquired a new stake in IQVIA in the third quarter worth about $30,000. Finally, Atlantic Union Bankshares Corp acquired a new stake in IQVIA in the third quarter worth about $36,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Price Performance

IQVIA stock opened at $160.70 on Friday. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. The firm has a market capitalization of $27.27 billion, a P/E ratio of 20.45, a PEG ratio of 1.74 and a beta of 1.39. The business has a 50-day moving average of $170.12 and a 200-day moving average of $203.01.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. During the same quarter in the previous year, the business posted $3.12 EPS. IQVIA’s revenue for the quarter was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 11.5 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on IQV shares. Jefferies Financial Group lowered their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 6th. UBS Group lowered their price objective on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price for the company in a research report on Friday, March 6th. JPMorgan Chase & Co. decreased their target price on IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. Finally, TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and boosted their target price for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA has an average rating of “Buy” and a consensus target price of $226.63.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.